Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1

Experimental Hematology

Volumn 32, Issue 1, 2004, Pages 76-86

  Schmidmaier, Ralf ^a   Oellerich, Mark ^a   Baumgart, Joachim ^b   Emmerich, Bertold ^a   Meinhardt, Gerold ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MEDAC GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ALKYLATING AGENT; BRYOSTATIN 1; CASPASE 3; DNA; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C DELTA; PROTEIN KINASE C INHIBITOR; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PATIENT; CELL CYCLE G1 PHASE; CELL DEATH; CELL FUNCTION; CELL LINE; CHEMOSENSITIVITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INCUBATION TIME; LEUKEMIA CELL; MALE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MODULATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REGULATORY MECHANISM;

EID: 0346938576     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2003.09.023     Document Type: Article

References (59)

1. Hiddemann W., Büchner T. Current status and perspectives of therapy for acute myeloid leukemia. Semin Hematol. 38:(suppl 6):2001;3-9.
2. Kiyoi H., Naoe T., Nakano Y., et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 93:1999;3074-3080.
3. Mizuki M., Fenski R., Halfter H., et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 96:2000;3907-3914.
4. Mesters R.M., Padro T., Bieker R., et al. Stable remission after administration of receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood. 98:2001;241-243.
5. Karp J.E., Lancet J.E., Kaufmann S.H., et al. Clinical and biologic activity of farnesyl transferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 97:2001;3361-3369.
6. Hass R., Bartels G., Meyer G., et al. TPA-induced differentiation and adhesion of U937 cells: changes in ultrastructure, cytoskeletal organization and expression of cell surface antigens. Eur J Cell Biol. 48:1989;282-293.
7. Lotem J., Cragoe E.J., Sachs L. Rescue from preprogrammed cell death in leukemic and normal myeloid cells. Blood. 78:1991;953-960.
8. Meinhardt G., Roth J., Hass R. Activation of protein kinase C relays distinct signaling pathways in the same cell type: differentiation and caspase-mediated apoptosis. Cell Death Differ. 7:2000;795-803.
9. Nelsestuen G.L., Bazzi M.D. Activation and regulation of protein kinase C enzymes. J Bioenerg Biomembr. 23:1991;43-61.
10. Blumberg P.M. Complexities of the protein kinase C pathway. Mol Carcinog. 4:1991;339-344.
11. Muramatsu M., Kaibuchi K., Arai K. Protein kinase C mutants in the auto-inhibitory region exhibit two distinct properties. FEBS Lett. 311:1992;75-79.
12. Zhang G., Kazanietz M.G., Blumberg P.M., Hurley J.H. Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester. Cell. 81:1995;917-924.
13. Meinhardt G., Roth J., Totok G. Protein kinase C activation modulates pro- and anti-apoptotic signaling pathways. Eur J Cell Biol. 79:2000;824-833.
14. Szallisi Z., Smith C.B., Pettit G.R., Blumberg P.M. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J Biol Chem. 269:1994;2118-2124.
15. Stone R.M., Sariban E., Pettit G.R., Kufe D.W. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood. 72:1988;208-213.
16. Hornung R.L., Pearson J.W., Beckwith M., Longo D.L. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res. 191:1993;472-478.
17. Zonder J.A., Shields A.F., Zalupski M., et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin Cancer Res. 7:2001;38-42.
18. Propper D.J., Macaulay V., O'Byrne K.J., et al. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer. 78:1998;1337-1341.
19. Jarvis W.D., Povirk L.F., Turner A.J., et al. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D- arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem Pharmacol. 47:1994;839-852.
20. Wang Z., Wang S., Dai Y., Grant S. Bryostatin 1 increases 1-beta-D-arabinofuranosyl- cytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-x(L). J Pharmacol Exp Ther. 301:2002;568-577.
21. Mohammad R.M., al-Katib A., Pettit G.R., Sensenbrenner L.L. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res. 54:1994;165-168.
22. Mohammad R.M., Diwakaran H., Maki A., et al. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res. 19:1995;667-673.
23. Grant S., Jarvis W.D., Swerdlow P.S., et al. Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA. Cancer Res. 52:1992;6270-6278.
24. Hartley J.A., O'Hare C.C., Baumgart J. DNA alkylation and interstrand cross-linking by treosulfan. Br J Cancer. 79:1999;264-266.
25. Merkle E., Ackermann S., Beck E.P., et al. High-dose versus low-dose cisplatin chemotherapy plus treosulfan in epithelial ovarian carcinoma FIGO II-IV. Results of a prospective randomized trial. Onkologie. 23:2000;232-238.
26. Köpf-Maier P., Saß G. Antitumor activity of treosulfan against human breast carcinomas. Cancer Chemother Pharmacol. 31:1992;103-110.
27. Köpf-Maier P., Saß G. Antitumor activity of treosulfan in human lung carcinomas. Cancer Chemother Pharmacol. 37:1996;211-221.
28. Rigos D., Wechsel H.W., Bichler K.H. Treosulfan in the treatment of metastatic renal cell carcinoma. Anticancer Res. 19:1999;1549-1552.
29. Casper J., Knauf W., Steiner D., et al. Toxicity reduced conditioning with treosulfan and fludarabine. Blood. 98:2001;187a.
30. Griskevicius L., Gaughan U., Canaparo R., et al. The myeloablative and immunosuppressive properties of treosulfan in mice. Blood. 98:2001;316b.
31. Harstrick A., Wilke H., Eberhardt W., et al. A phase I dose escalation trial of intravenous treosulfan in refractory cancer. Onkologie. 19:1996;153-156.
32. Hilger R.A., Harstrick A., Eberhardt W., et al. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol. 42:1998;99-104.
33. Scheulen M.E., Hilger R.A., Oberhoff C., et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res. 6:2000;4209-4216.
34. Hass R., Gunji H., Datta R., et al. Differentiation and retrodifferentiation of human myeloid leukemia cells is associated with reversible induction of cell cycle-regulatory genes. Cancer Res. 52:1992;1445-1450.
35. Bojko P., Scheulen M.E., Hilger R., Oberhoff C., Schindler A.E., Seeber S. High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer. Cancer Res Clin Oncol. 127:2001;243-250.
36. Meinhardt G., Dayyani F., Jahrsdorfer B., Baumgart J., Emmerich B., Schmidmaier R. Treosulfan is an effective inducer of cell death in myeloma cell lines and primary myeloma cells from patients. Br J Haematol. 122:2003;892-899.
37. Beelen D.W., Trenschel R., Casper J., et al. Evaluation of safety, efficacy and pharmacokinetics of dose-escalated Treosulfan (TREO)/ Cyclophosphamide (CY) conditioning prior to allogeneic transplantation of high-risk leukemia patients. [abstract] Blood. 100:2002;415a. Abstract 1608.
38. Kaldor J.M., Day N.E., Pettersson F., et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med. 322:1990;1-6.
39. Kaldor J.M., Day N.E., Hemminki K. Quantifying the carcinogenicity of antineoplastic drugs. Eur J Cancer Clin Oncol. 24:1988;703-711.
40. Feit P.W. Stereoisomere 1,4-di-O-methansulfonyl-butan-1,2,3,4-tetrole. Tetrahedron Lett. 20:1961;716-717.
41. Feit P.W. 1,4-Bismethanesulfonates of the stereoisomeric butanetetrols and related compounds. J Med Chem. 7:1964;14-17.
42. Feit P.W., Rastrup-Anderson N., Matagne R. Studies in epoxide formation from (2S,3S)-threitol-1,4-bismethanesulfonate. The preparation and biological activity of 2S,3S-1,2-epoxy-3,4-butanendiol-4-methanesulfonate. J Med Chem. 13:1970;1173-1175.
43. Hennings H., Blumberg P.M., Pettit G.R., Herald C.L., Shores R., Yuspa S.H. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis. 8:1987;1343-1346.
44. Emoto Y., Manome Y., Meinhardt G., et al. Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J. 14:1995;6148-6156.
45. Meinhardt G., Roth J., Totok G., Auner H., Emmerich B., Hass R. Signaling defect in the activation of caspase-3 and PKCδ in human TUR leukemia cells is associated with resistance to apoptosis. Exp Cell Res. 247:1999;534-542.
46. Hass R., Hirano M., Kharabanda S., Rubin E., Meinhardt G., Kufe D. Resistance to phorbol ester-induced differentiation of a U937 myeloid leukemia cell variant with a signaling defect upstream of Raf-1 kinase. Cell Growth Differ. 4:1993;657-663.
47. Hass R., Prudovsky I., Kruhoffer M. Differential effects of phorbol ester on signaling and gene expression in human leukemia cells. Leukemia Res. 1997;589-594.
48. Ruvolo P.P., Deng X., Carr B.K., May W.S. A functional role for mitochondrial protein kinase C-alpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem. 273:1998;25436-25442.
49. Berkow R.L., Kraft A.S. Bryostatin, a non-phorbol macrocyclic lactone, activates intact human polymorphonuclear leukocytes and binds to the phorbol ester receptor. Biochem Biophys Res Commun. 131:1985;1109-1116.
50. Kazanietz M.G., Lewin N.E., Gao F., Pettit G.R., Blumberg P. Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes. Mol Pharmacol. 46:1994;374-379.
51. Wang S., Vrana J.A., Bartimole T.M., et al. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D- arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Mol Pharmacol. 52:1997;1000-1009.
52. Szallasi Z., Du L., Levine R., et al. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-dependent mechanism: dissociation of activities using 16-epi-bryostatin 1. Cancer Res. 56:1996;2105-2111.
53. Mohammed R.M., Beck F.W., Katato K., Hamdy N., Wall N., Al-Katib A. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5′-NT and Bax/Bcl-2. Biol Chem. 379:1998;1253-1261.
54. Al-Katib A.M., Smith M.R., Kamanda W.S., et al. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res. 4:1998;1305-1314.
55. La Porta C.A., Dolfini E., Comolli. Inhibition of protein kinase C-α isoform enhances the P-glycoprotein expression and the survival of LoVo human colon adenocarcinoma cells to doxorubicin exposure. Br J Cancer. 78:1998;1283-1287.
56. Weitman S., Mangevin A.M., Berkow R.L., et al. A phase I trial of bryostatin-1 in children with refractory solid tumors: a pediatric oncology group study. Clin Cancer Res. 5:1999;2344-2348.
57. Elgie A.W., Sargent J.M., Alton P., et al. Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML. Leuk Res. 22:1998;373-378.
58. Grant S., Jarvis W.D., Turner A.J., Wallace H.J., Pettit G.R. Effects of bryostatin 1 and rGM-CSF on the metabolism of1-beta-D-arabinofuranosylcytosine in human leukaemic myeloblasts. Br J Haematol. 82:1992;522-528.
59. Meinhardt G., Eppinger E., Schmidmaier R. Effect of novel modulators of protein kinase C activity upon chemotherapy-induced differentiation and apoptosis in myeloid leukemic cells. Anticancer Drugs. 13:2002;725-733.